Health Care / Medicine
-
Government, Health Care / Medicine
Reading The Tea Leaves For Cannabis Regulation
A decade after the first recreational marijuana dispensaries opened, will 2024 be the year that cannabis finally gets a get-out-of-jail-for-free card? -
Courts, Health Care / Medicine
Walgreens To Pay Humana $360M To Settle Claims It Overcharged For Drugs
Walgreens has agreed to pay Humana $360 million to settle a drug pricing dispute that has spanned nearly five years. The payout is roughly half of what Walgreens was originally ordered to pay when the issue was first resolved last year. - Sponsored
The Business Case For AI At Your Law Firm
ChatGPT ushers in the age of generative AI – even for law firms. -
Health Care / Medicine
How Can Hospitals Make The Post-Merger Transition As Smooth As Possible?
Experts have predicted that 2024 will be an eventful year for hospital M&A activity. As the industry prepares for another big year, there are a few things that health system leaders involved in these deals should keep in mind to make the process as smooth as possible, according to DexCare CEO Derek Streat.
-
Government, Health Care / Medicine
19 Senators Urge HHS To Drop Appeal That Would Jeopardize Americans’ Access To Life-Saving Drugs
A bipartisan group of senators sent a letter to HHS asking it to rethink its appeal of a recent federal district court decision that limits the use of ‘copay accumulators’ — which are programs insurers use to prevent medication copay assistance from counting toward patients’ deductibles or out-of-pocket maximums. -
Health Care / Medicine
Both Have Done Wrong, Expert Says On UHC/Mount Sinai Contract Dispute
Mount Sinai is out of network for UnitedHealthcare's employer-sponsored and individual plans as of January 1 due to a payment dispute. Both parties are likely at fault for getting to this point, one expert declared. -
Finance, Health Care / Medicine
Goldman Sachs Closes $650M Fund To Invest In ‘Golden Era’ Pf Biotech Innovation
Goldman Sachs’s new fund—its first dedicated to life sciences—will focus on early- to mid-stage therapeutics companies with multiple assets. Genetic medicine, cell therapy, immunotherapy, and artificial intelligence are among the areas of investment interest for the firm. -
Health Care / Medicine
Oliver Wyman: 5 ACA Trends To Watch Over The Next Decade
A recent Oliver Wyman report laid out five Affordable Care Act trends to watch, including the rise of ICHRAs and the need for a ‘seamless member experience.’ -
Finance, Health Care / Medicine, Technology
West Monroe’s 3 Healthcare Outlooks For 2024: AI, Cost Pressures, Dealmaking
There are three key trends for the healthcare industry to follow in 2024, including the rise of AI, increasing cost pressures, and M&A activity, according to West Monroe. - Sponsored
Early Adopters Of Legal AI Gaining Competitive Edge In Marketplace
How to best leverage generative AI as an early adopter with ethical use. -
Finance, Health Care / Medicine
5 Most Notable Hospital M&A Deals In 2023
Health systems have made dozens of M&A deals this year, as many are seeking out partnerships to grow and protect their long-term financial sustainability. Here is a rundown of five newsworthy deals announced in 2023. -
Health Care / Medicine
Inside Planned Parenthood’s Partnership-Centric Approach To Expanding Abortion Access
Ambreen Molitor, Planned Parenthood’s national director of venture and innovation, discussed three partnerships her organization has launched this year to address barriers to abortion care. These partnerships tackle barriers such as cost, changing state laws and lack of emotional support. -
Health Care / Medicine
2023’s Wins And Losses In The Reproductive Health Space, Per 2 Advocates
Representatives from the Guttmacher Institute and NFPRHA shared their wins and losses for reproductive health in 2023. Their wins include states moving to protect contraception and the approval of Opill, while their losses include state enactments of abortion bans and the lack of funding for Title X. -
Health Care / Medicine
Arcadia Sells Its Value-Based Care Division To A Fledgling Startup
Guidehealth, a nascent value-based care enablement startup, acquired Arcadia’s value-based care service division. Acquiring this business unit allows Guidehealth to provide health systems with a platform that helps them succeed in value-based care arrangements while still maintaining their patient volume levels. -
Finance, Health Care / Medicine
What Will Digital Health Investment Look Like In 2024?
Healthcare's share of the global PE and VC deal count will likely continue decreasing in 2024, according to a new Pitchbook report. The report also predicted that generative AI and surgical robotics will continue to be hot areas of interest for investors, and that there will be at least three digital health IPOs next year.
Sponsored
Sponsored
Is The Future Of Law Distributed? Lessons From The Tech Adoption Curve
The rise of remote work has dramatically reshaped the relationship between Lawyers and Law Firms, see how Scale LLP has taken the steps to get…
Sponsored
Legal AI: 3 Steps Law Firms Should Take Now
If 2023 introduced legal professionals to generative AI, then 2024 will be when law firms start adapting to utilize it. Things are moving fast, so…
Sponsored
Early Adopters Of Legal AI Gaining Competitive Edge In Marketplace
How to best leverage generative AI as an early adopter with ethical use.
Sponsored
Sponsored
Navigating Financial Success by Avoiding Common Pitfalls and Maximizing Firm Performance
In this CLE-eligible webinar, we’ll explore the most common accounting pitfalls and how to avoid them for your firm.
Sponsored
The Business Case For AI At Your Law Firm
ChatGPT ushers in the age of generative AI – even for law firms.
-
Government, Health Care / Medicine
Why A Former ONC Chief Thinks TEFCA Is Inherently Flawed
Last week, the ONC announced that TEFCA had finally gone live. This followed years of the ONC heralding the project's potential to boost interoperability and increase patients’ access to their healthcare data. However, former ONC Chief Don Rucker believes that TEFCA is built on an archaic data exchange protocol that will prevent the initiative from being useful. -
Health Care / Medicine
Illumina’s Antitrust Battles To End With Divestiture Of Cancer Test Maker Grail
Illumina has decided against further appeals of U.S. and European antitrust litigation challenging its acquisition of liquid biopsy company Grail. Illumina expects to have terms of the divestiture set by the end of the second quarter of 2024. -
Government, Health Care / Medicine
A Step Too Far: Congress Must Act On Insurance Company Tactics That Delay Critical Care For Patients
This bipartisan legislation will help create a more transparent process that allows patients and physicians to seek exceptions to step therapy protocol. Although it only applies to employer-sponsored health plans, the bill represents an important step towards reining in this troubling practice. -
Government, Health Care / Medicine
Sanofi Abandons Deal For Rare Disease Drug Amid FTC’s Monopoly Concerns
Sanofi, which markets the two primary treatments for Pompe disease, was trying to add a third one by licensing rights to a Maze Therapeutics drug candidate with a different therapeutic approach. A Federal Trade Commission complaint alleges the deal amounts to a monopoly player taking out its competition. -
Government, Health Care / Medicine
Bipartisan Price Transparency Bill Passes In House
The Lower Costs, More Transparency Act has passed in the House with bipartisan support. The action is being applauded from several advocacy organizations. -
Health Care / Medicine
Fruit Street Health Sues Sharecare For $25M
Fruit Street Health's complaint alleged that Sharecare violated the terms of their shared business agreement by rolling out its own version of Fruit Street’s diabetes prevention program, which had been previously offered to Sharecare members. Sharecare said that the lawsuit is baseless. -
Health Care / Medicine
Expert: The Rumored Humana/Cigna Combination Makes Sense
With Cigna mostly focused on the commercial market and Humana mostly focused on the Medicare Advantage market, the rumored combination talks check out, according to one industry expert.